1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Formycon Believes Itself Among Frontrunners For Mammoth Keytruda Opportunity

German Firm Distances Comparisons With Saturated Humira Development Pool

 
• By Dean Rudge

On the back of early success with its biosimilar to Lucentis (ranibizumab), Formycon has looked further into the future and divulged details on the set-to-be competitive race to develop a biosimilar to Merck & Co’s €10bn ($10.9bn) PD-1 inhibitor Keytruda (pembrolizumab).

Shutterstock

Germany-based pure-play biosimilars developer Formycon believes it will see “eight to ten competitors max” in the race to develop a biosimilar to Merck & Co’s €10bn ($10.9bn) PD-1 inhibitor Keytruda (pembrolizumab), in contrast to the more saturated development pool for Humira (adalimumab), ahead of plans to kick off clinical trials for its FYB206 pembrolizumab biosimilar candidate at the end of this year or early in 2025.

Meanwhile, Formycon’s management told the recent J.P

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Amgen Locked Out Of Canadian Eculizumab Market Until 2027

 
• By Dean Rudge

Rejecting Amgen’s challenges on the grounds of anticipation and obviousness, Canada’s Federal Court has issued an injunction against the biosimilars firm until patent expiry in March 2027.

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

More from Products